Methofill

Methotrexate, the active ingredient in Methofill, is an antimetabolite presented as a subcutaneous injection for subcutaneous use. Classified as a disease‑modifying antirheumatic drug (DMARD), it is indicated for rheumatoid arthritis, psoriasis, selected cancers and ectopic pregnancy, and is marketed in the European Union.

GNH USA supplies Methofill as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality assurance, regulatory conformity and reliable cold‑chain logistics.

Methofill (methotrexate) is used in conditions where inhibition of rapidly dividing cells or immune modulation is required.

- Rheumatoid arthritis: reduces joint inflammation and slows disease progression. - Psoriasis: decreases skin plaque formation and severity. - Acute lymphoblastic leukemia: interferes with malignant cell proliferation. - Non‑Hodgkin lymphoma: contributes to tumor control. - Ectopic pregnancy: terminates trophoblastic tissue.

Methofill may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Fatigue: reduced energy levels. - Mouth sores: oral ulceration. - Elevated liver enzymes: mild hepatic enzyme rise.

Serious or Rare Side Effects: - Bone marrow suppression: pancytopenia, increased infection risk. - Pulmonary toxicity: interstitial pneumonitis or fibrosis. - Severe hepatic injury: hepatitis or liver failure.

When prescribing Methofill, clinicians should observe several safety precautions to minimize risk.

- Renal function: assess creatinine clearance before initiation and monitor regularly. - Hepatic status: evaluate liver enzymes and avoid use in severe hepatic impairment. - Pregnancy: contraindicated in pregnancy (Category X); ensure effective contraception. - Infections: screen for latent tuberculosis and avoid use in active infections. - Drug monitoring: perform complete blood counts frequently to detect marrow suppression. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Methofill can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase risk of renal toxicity. - High‑dose penicillins: may reduce methotrexate clearance, raising toxicity. - Proton pump inhibitors (omeprazole): can impair renal elimination, enhancing toxicity.

Moderate Interactions (Monitor Closely): - Sulfonamides: may potentiate myelosuppression. - Trimethoprim‑sulfamethoxazole: increased risk of bone marrow suppression. - Azathioprine: additive immunosuppression. - Live vaccines: heightened infection risk.